Zacks: Brokerages Expect Cardiff Oncology, Inc. (NASDAQ:CRDF) Will Announce Quarterly Sales of $80,000.00

Brokerages expect Cardiff Oncology, Inc. (NASDAQ:CRDFGet Rating) to report sales of $80,000.00 for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Cardiff Oncology’s earnings, with estimates ranging from $50,000.00 to $100,000.00. Cardiff Oncology posted sales of $70,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 14.3%. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Cardiff Oncology will report full year sales of $300,000.00 for the current year, with estimates ranging from $220,000.00 to $370,000.00. For the next year, analysts expect that the business will report sales of $200,000.00. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Cardiff Oncology.

Cardiff Oncology (NASDAQ:CRDFGet Rating) last released its quarterly earnings data on Friday, May 6th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Cardiff Oncology had a negative return on equity of 25.12% and a negative net margin of 9,447.37%.

A number of equities research analysts recently issued reports on CRDF shares. HC Wainwright decreased their price objective on shares of Cardiff Oncology from $25.00 to $22.00 in a report on Monday, May 9th. Maxim Group decreased their price target on Cardiff Oncology from $25.00 to $14.00 in a research note on Monday, January 24th. Zacks Investment Research downgraded Cardiff Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, May 11th. Finally, Robert W. Baird decreased their target price on Cardiff Oncology from $13.00 to $9.00 in a research report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $13.00.

Several large investors have recently modified their holdings of CRDF. Point72 Asset Management L.P. bought a new position in shares of Cardiff Oncology in the fourth quarter worth about $3,015,000. Renaissance Technologies LLC bought a new position in Cardiff Oncology in the 1st quarter worth approximately $1,219,000. Morgan Stanley increased its position in Cardiff Oncology by 1,741.2% in the 2nd quarter. Morgan Stanley now owns 467,461 shares of the company’s stock worth $3,109,000 after buying an additional 442,072 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Cardiff Oncology by 12.1% during the third quarter. Janus Henderson Group PLC now owns 3,533,381 shares of the company’s stock worth $23,541,000 after buying an additional 382,214 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Cardiff Oncology in the first quarter valued at approximately $805,000. 56.43% of the stock is currently owned by institutional investors.

Shares of CRDF opened at $1.32 on Tuesday. The company’s fifty day moving average is $1.97 and its 200-day moving average is $3.84. Cardiff Oncology has a 12 month low of $1.13 and a 12 month high of $8.92.

About Cardiff Oncology (Get Rating)

Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Featured Stories

Get a free copy of the Zacks research report on Cardiff Oncology (CRDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardiff Oncology (NASDAQ:CRDF)

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.